Tezepelumab clinical trials
Tezepelumab is named as an intervention in 15 current clinical trials in our China, USA, Canada, France, Italy, Denmark, UK, Germany, Spain, Netherlands, Brazil, Japan, Belgium, Sweden, Austria, Czechia, Australia, Israel, Poland, Turkey, Mexico, South Korea, Norway, India and Taiwan registers. 9 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (8). The most-studied condition is Asthma. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Tezepelumab is approved
All regulators →Of the three regulators tracked here, the first to approve Tezepelumab was the US, on 17 Dec 2021. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Tezepelumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Tezepelumab works
All drug targets →- Thymic stromal lymphopoietin inhibitor InhibitorTarget: TSLP thymic stromal lymphopoietinChEMBL only
- Chronic obstructive pulmonary diseasePhase 3
- Chronic rhinosinusitis with nasal polypsPhase 3
- Eosinophilic esophagitisPhase 3
- Allergic rhinitisPhase 2
- Atopic eczemaPhase 2
- Chronic idiopathic urticariaPhase 2
- Eosinophilic granulomatosis with polyangiitisPhase 2
- Peanut allergic reactionPhase 2
- Allergic diseasePhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3707229, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8933, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Tezepelumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Tezepelumab. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Tezepelumab for treating severe asthma NICE TA880 | Optimised | 20 Apr 2023 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Tezepelumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: TezspireEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Tezepelumab
15 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Tezepelumab in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Tezepelumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
2025-524741-28-00 · CTIS ↗ · Respiratory Tract Diseases
|
Phase 4 | Authorised | Amsterdam UMC Stichting | Netherlands |
|
Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting
2025-524495-39-00 · CTIS ↗ · Otorhinolaryngologic Diseases
|
Phase 4 | Authorised | Medical University Of Vienna | Austria |
Tezepelumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Tezepelumab on the HPRA medicines list.
- Tezspire 210 mg solution for injection in pre-filled syringeAstraZeneca AB · EU/1/22/1677/001-002
Supply shortages
No entry for Tezepelumab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Tezepelumab
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Asthma | 3 |
| Severe Asthma | 3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 |
| Chronic Rhinosinusitis With Nasal Polyps | 2 |
| Eosinophilic Esophagitis | 1 |
| Cardiovascular Events | 1 |
| MACE | 1 |
| Allergic Bronchopulmonary Aspergillosis | 1 |
| ABPA | 1 |
| Bronchiolitis Obliterans Syndrome (BOS) | 1 |
| HSCT | 1 |
| Bronchial Disease | 1 |
| Asthma Bronchiale | 1 |
| Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 1 |
| Asthma With Allergic Rhinitis | 1 |
| Pulmonary Disease | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 8 |
| Qianfoshan Hospital | 1 |
| University Hospital, Lille | 1 |
| Hopital Foch | 1 |
| Medical University of Vienna | 1 |
| Dr. Anne Ellis | 1 |
| University of Alberta | 1 |
| Taichung Veterans General Hospital | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Tezepelumab trials
How many clinical trials are testing Tezepelumab?
15 current trials in our China, USA, Canada, France, Italy, Denmark, UK, Germany, Spain, Netherlands, Brazil, Japan, Belgium, Sweden, Austria, Czechia, Australia, Israel, Poland, Turkey, Mexico, South Korea, Norway, India and Taiwan registers name Tezepelumab (also registered as MEDI9929 and AMG157) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Tezepelumab trials recruiting patients?
Yes. 9 of the 15 trials are recruiting: 4 with sites in China, 4 with sites in USA, 3 with sites in Canada, 4 with sites in France, 2 with sites in Italy, 3 with sites in Denmark, 2 with sites in UK, 2 with sites in Germany, 2 with sites in Spain, 2 with sites in Netherlands, 2 with sites in Brazil, 2 with sites in Japan, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Czechia, 1 with sites in Australia, 1 with sites in Israel, 2 with sites in Poland, 2 with sites in Turkey, 2 with sites in Mexico, 2 with sites in South Korea, 1 with sites in India and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tezepelumab clinical trials?
AstraZeneca (8), Qianfoshan Hospital (1), University Hospital, Lille (1) and Hopital Foch (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Tezepelumab licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Tezepelumab, for example Tezspire 210 mg solution for injection in pre-filled syringe (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Tezepelumab shortage?
Not in the lists we track: Tezepelumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tezepelumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tezepelumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tezepelumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.